Worldwide Healthcare Trust announces Dr Bina Rawal to its Board as upcoming Independent Director

– UK, London –  Worldwide Healthcare Trust PLC (LON: WWH) today announced the appointment of Dr Bina Rawal as an independent Director of the Company, with effect from Friday, 1 November 2019.

Dr Rawal will be a member of the Audit Committee, the Nominations Committee and the Management Engagement & Remuneration Committee on appointment.

Sir Martin Smith, Chairman, commented: “My fellow Directors and I are delighted to welcome Bina to the Board. We are very pleased to have appointed a Director with such a breadth of experience in the pharmaceutical industry that traverses all phases of drug discovery and development and all therapy areas.”

Dr Rawal’s appointment will be proposed to shareholders for election at the Annual General Meeting of the Company to be held on July 2020.

About Dr Bina Rawal

Dr Rawal, a physician with 25 years’ experience in life sciences research and development, has held senior executive roles in drug development and scientific evaluation in four global pharmaceutical companies. She also has worked in senior roles with two medical research funding organisations: Wellcome Trust and Cancer Research UK.

She is currently a non-executive Director of the Innovation Agency where she supports the adoption and spread of innovation within the NHS. She is also a Trustee of two educational charities: the Social Mobility Foundation and the Children’s University Trust and commences her membership of the Council of St George’s University of London in October 2019, having been a member of Council at the University of Reading.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.